Effect of administration of a phospholipid emulsion on the initial response of horses administered endotoxin

American Journal of Veterinary Research

Volumn 63, Issue 10, 2002, Pages 1370-1378

  Winchell, Wyatt W ^a   Hardy, Joanne ^a   Levine, Daniel M ^a   Parker, Thomas S ^a   Gordon, Bruce R ^a   Saal, Stuart D ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ESCHERICHIA COLI ENDOTOXIN; INTERLEUKIN 6; LIPID EMULSION; PHOSPHOLIPID; ROGOSIN; SODIUM CHLORIDE; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ANALYSIS OF VARIANCE; ANIMAL CELL; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG DOSAGE FORM; DRUG EFFECT; ENDOTOXEMIA; FEVER; HEART OUTPUT; HEART RATE VARIABILITY; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMIC MONITORING; HORSE; INFUSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG ARTERY PRESSURE; NONHUMAN; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; REACTION TIME; RECTUM TEMPERATURE;

ANIMALIA; EQUIDAE; EQUUS CABALLUS; ESCHERICHIA COLI;

EID: 0036794566     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.1370     Document Type: Article

References (58)

1. King JN, Gerring EL. Detection of endotoxin in cases of equine colic. Vet Rec 1988;123:269-271.
2. Meyers K, Reed S, Keck M, et al. Circulating endotoxin-like substance(s) and altered hemostasis in horses with gastrointestinal disorders: an interim report. Am J Vet Res 1982;43:2233-2238.
3. Moore JN, Garner HE, Berg JN, et al. Intracecal endotoxin and lactate during the onset of equine laminitis: a preliminary report. Am J Vet Res 1979;40:722-723.
4. Moore JN. Recognition and treatment of endotoxemia. Vet Clin North Am Equine Pract 1988;4:105-113.
5. Moore JN, Morris DD. Endotoxemia and septicemia in horses: experimental and clinical correlates. J Am Vet Med Assoc 1992;200:1903-1914.
6. Raetz CR, Ulevitch RJ, Wright SD, et al. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 1991;5:2652-2660.
7. Tobias PS, Ulevitch RJ. Lipopolysaccharide binding protein and CD14 in LPS-dependent macrophage activation. Immunobiology 1993;187:227-232.
8. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990;249: 1429-1431.
9. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-1433.
10. Heumann D, Gallay P, Barras C, et al. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992;148:3505-3512.
11. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999;274:10689-10692.
12. Barton MH, Collatos C, Moore JN. Endotoxin-induced expression of tumour necrosis factor, tissue factor and plasminogen activator inhibitor activity by peritoneal macrophages. Equine Vet J 1996;28:382-389.
13. Morris DD, Crowe N, Moore JN. Correlation of clinical and laboratory data with serum tumor necrosis factor activity in horses with experimentally induced endotoxemia. Am J Vet Res 1990;51: 1935-1940.
14. Clark ES, Moore JN. The effects of slow infusion of a low dosage of endotoxin in healthy horses. Equine Vet J Suppl 1989;7:33-37.
15. Bertone JJ, Gossett KA, Shoemaker KE, et al. Effect of hypertonic vs isotonic saline solution on responses to sublethal Escherichia coli endotoxemia in horses. Am J Vet Res 1990;51:999-1007.
16. Bottoms GD, Fessler JF, Roesel OF, et al. Endotoxin-induced hemodynamic changes in ponies: effects of flunixin meglumine. Am J Vet Res 1981;42:1514-1518.
17. Fessler JF, Bottoms GD, Roesel OF, et al. Endotoxin-induced change in hemograms, plasma enzymes, and blood chemical values in anesthetized ponies: effects of flunixin meglumine. Am J Vet Res 1982;43:140-144.
18. Moore JN, Hardee MM, Hardee GE. Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor. Am J Vet Res 1986;47:110-113.
19. Templeton CB, Bottoms GD, Fessler JF, et al. Endotoxin-induced hemodynamic and prostaglandin changes in ponies: effects of flunixin meglumine, dexamethasone, and prednisolone. Circ Shock 1987;23:231-240.
20. Drummond WH. Neonatal shock: pathophysiology and management. In: Koterba AM, Drummond WH, Kosch PC, eds. Equine clinical neonatology. Philadelphia: Lea & Febiger, 1990;106-123.
21. Baxter GM, Moore JN. Effect of aspirin on ex vivo generation of thromboxane in healthy horses. Am J Vet Res 1987;48:13-16.
22. Moore BR, Hinchcliff KW. Heparin: a review of its pharmacology and therapeutic use in horses. J Vet Intern Med 1994;8:26-35.
23. Baskett A, Barton MH, Norton N, et al. Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 1997;58:1291-1299.
24. Morris DD, Whitlock RH, Corbeil LB. Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 1986;47:544-550.
25. Spier SJ, Lavoie JP, Cullor JS, et al. Protection against clinical endotoxemia in horses by using plasma containing antibody to an Rc mutant E. coli (J5). Circ Shock 1989;28:235-248.
26. Durando MM, MacKay RJ, Linda S, et al. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 1994;55:921-927.
27. MacKay RJ, Clark CK, Logdberg L, et al. Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. Am J Vet Res 1999;60:68-75.
28. Cargile JL, MacKay RJ, Dankert JR, et al. Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of miniature horses given endotoxin. Am J Vet Res 1995;56:1451-1459.
29. Cargile JL, MacKay RJ, Dankert JR, et al. Effects of tumor necrosis factor blockade on interleukin 6, lactate, thromboxane, and prostacyclin responses in miniature horses given endotoxin. Am J Vet Res 1995;56:1445-1450.
30. Bunnell E, Lynn M, Habet K, et al. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 2000;28:2713-2720.
31. Flegel WA, Wolpl A, Mannel DN, et al. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989;57:2237-2245.
32. Gordon BR, Parker TS, Levine DM, et al. Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia. Crit Care Med 1996;24:584-589.
33. van Leeuwen HJ, van Beek AP, Dallinga-Thie GM, et al. The role of high density lipoprotein in sepsis. Neth J Med 2001;59:102-110.
34. Parker TS, Levine DM, Chang JC, et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect Immun 1995;63:253-258.
35. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high-density lipoprotein. Proc Natl Acad Sci U S A 1993;90:12040-12044.
36. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996;184:1601-1608.
37. Sprouse RF, Garner HE, Green EM. Plasma endotoxin levels in horses subjected to carbohydrate induced laminitis. Equine Vet J 1987;19:25-28.
38. Allen GK, Green EM, Robinson JA, et al. Serum tumor necrosis factor alpha concentrations and clinical abnormalities in colostrum-fed and colostrum-deprived neonatal foals given endotoxin. Am J Vet Res 1993;54:1404-1410.
39. Muir WW, Skarda RT, Milne DW. Estimation of cardiac output in the horse by thermodilution techniques. Am J Vet Res 1976; 37:697-700.
40. Allen GK, Campbell-Beggs C, Robinson JA, et al. Induction of early-phase endotoxin tolerance in horses. Equine Vet J 1996; 28:269-274.
41. Barton MH, Bruce EH, Moore JN, et al. Effect of tumor necrosis factor antibody given to horses during early experimentally induced endotoxemia. Am J Vet Res 1998;59:792-797.
42. MacKay RJ, Lester GD. Induction of the acute-phase cytokine, hepatocyte-stimulating factor/interleukin 6, in the circulation of horses treated with endotoxin. Am J Vet Res 1992;53:1285-1289.
43. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;163:1433-1450.
44. Bottoms GD, Adams HR. Involvement of prostaglandins and leukotrienes in the pathogenesis of endotoxemia and sepsis. J Am Vet Med Assoc 1992;200:1842-1848.
45. Tempel GE, Strong JW, Wise WC, et al. The role of eicosanoids in mediating blood flow alterations in endotoxin shock. Prog Clin Biol Res 1989;299:33-42.
46. Worthen GS, Avdi N, Vukajlovich S, et al. Neutrophil adherence induced by lipopolysaccharide in vitro. Role of plasma component interaction with lipopolysaccharide. J Clin Invest 1992;90:2526-2535.
47. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662-675.
48. Kitchens RL, Wolfbauer G, Albers JJ, et al. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999;274:34116-34122.
49. Morris DD, Moore JN, Crowe N, et al. Effect of experimentally induced endotoxemia on serum interleukin-6 activity in horses. Am J Vet Res 1992;53:753-756.
50. LeMay LG, Vander AJ, Kluger MJ. Role of interleukin 6 in fever in rats. Am J Physiol 1990;258:R798-R803.
51. Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251-7255.
52. May SA, Hooke RE, Lees P. Inhibition of interleukin-1 activity by equine synovial fluid. Equine Vet J 1992;24:99-102.
53. Morris EA, McDonald BS, Webb AC, et al. Identification of interleukin-1 in equine osteoarthritic joint effusions. Am J Vet Res 1990;51:59-64.
54. Swiderski CE, Sobol G, Lunn DP, et al. Molecular cloning, sequencing, and expression of equine interleukin-6. Vet Immunol Immunopathol 2000;77:213-220.
55. Hardy J, Bertone AL, Malemud CJ. Effect of synovial membrane infection in vitro on equine synoviocytes and chondrocytes. Am J Vet Res 1998;59:293-299.
56. Bottoms GD, Templeton CB, Fessler JF, et al. Thromboxane, prostaglandin 12 (epoprostenol), and the hemodynamic changes in equine endotoxin shock. Am J Vet Res 1982;43:999-1002.
57. Glew RH. Lipid metabolism II: pathways of metabolism of special lipids. In: Devlin TM, ed. Textbook of biochemistry. New York: John Wiley & Sons, 1992;462-465.
58. McCann ME, Moore JN, Carrick JB, et al. Effect of intravenous infusion of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid composition and inflammatory mediator production in vitro. Shock 2000;14:222-228.